Bayer ( BAYRY ) announced that positive results from long-term extension studies (CHEST-2 and PATENT-2) on Adempas were presented at the European Respiratory Society (ERS) Congress. These studies are evaluating Adempas for the treatment of patients suffering from inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent or recurrent CTEPH after surgery and in pulmonary arterial hypertension (PAH) patients.
Data from the studies revealed that treatment with Adempas showed sustained improvements in exercise capacity and WHO Functional Class (FC) similar to phase III CHEST-1 and PATENT-1 study results. Moreover, Adempas was generally well tolerated, having a good safety profile in the extension studies.
We note that Adempas is already approved in the U.S., EU and several other countries for the CTEPH and PAH indications. The drug contributed around €23 million to Bayer's top line in the second quarter of 2014.
The addition of products like Xarelto, Eylea, Xofigo, Adempas and Stivarga has given a boost to the HealthCare segment at Bayer. All these products have performed encouragingly since their launch and are expected to do so in the future.
These new products are expected to contribute around €2.8 billion to segmental sales in 2014. The company is also looking to expand their label beyond current indications. Label expansion of these drugs will drive growth further.
Bayer presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Allergan Inc. ( AGN ), Endo International ( ENDP ) and Gilead Sciences Inc. ( GILD ). All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.